Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

A Randomized, Double-blind, Placebo-Controlled, Escalating Single Dose, Phase 1 & Phase 2 Study to Evaluate the Safety and Efficacy of Inhaled IBIO123 in Participants With Severe COVID-19 Illness

This is a Phase 1 and phase 2, adaptive, placebo-controlled, double-blind, randomized single-dose study in participants with Severe COVID-19 illness.

Study Overview

• Status: Completed
• Conditions: COVID-19
• Intervention / Treatment: Other: Placebo; Biological: IBIO123

Detailed Description

In Phase 1, in hospital in a continuous observation setting the first cohort will recruit a total of 8 participants who will receive a single inhaled administration of the study treatment. This cohort will consist of 6 participants on active treatment at a dose of 5mg (0.5cc) of IBIO123 and 2 participants on placebo (0.5cc). Participants will be followed for a total duration of 7 days which is greater than 5 expected half-lives of the study drug in lungs. Therefore, after 7 days, negligible amount of the study drug should remain in the lungs of participants. Safety data will be collected and reviewed by a Data Monitoring Committee (DMC). If no stopping rules have been met, the DMC will recommend the dosing of the second cohort at the expected therapeutic dose of 10mg. If stopping rules have been met the DMC will recommend the termination of the study.

The second cohort will be recruited in hospital in continuous observation setting and recruit a total of 8 participants who will receive a single inhaled administration of the study treatment. This cohort will consist of 6 participants on active treatment at a dose of 10mg of IBIO123 (1 cc) and 2 participants on placebo (1 cc).

Participants will be followed for a total duration of 7 days which is greater than 5 expected half-lives of the study drug in lungs. Therefore, after 7 days, negligible amount of the study drug should remain in the lungs of participants. Safety data will be collected and reviewed by a Data Monitoring Committee (DMC). If no stopping rules have been met the DMC will recommend the phase 2 dose of 10mg. If stopping rules have been met the DMC will recommend a phase 2 dose of 5 mg.

In Phase 2, in the lead-in portion of the phase 2, the DMC will meet 7 days after the first 9 subjects (3 Placebo and 6 Active) have completed their day 7 visit to review safety information of these subjects that have been dosed with 10mg of IBIO123 on Days 1 and 3. If this dose regimen is deemed safe by the DMC, the phase 2 study enrolment will pursue and be completed at 10mg on Day 1 and 10 mg on Day 3. If stopping rules were obtained during the Safety review, the study enrolment will be pursued with a single dose of 10mg of IBIO 123 on Day 1.

• Study Type: Interventional
• Enrollment (Actual): 123
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• South Africa
  • Centurion
    • Lyttelton, Centurion, South Africa, 0157
      • JOHESE UNITAS Hospital
  • Gauteng
    • Pretoria, Gauteng, South Africa, 0002
      • JOHESE ZAH Hospital
• Ukraine
  • Ivano-Frankivsk Oblast
    • Ivano-Frankivs'k, Ivano-Frankivsk Oblast, Ukraine, 76018
      • City Clinical Hospital #1 of Ivano-Frankivsk City Council
    • Ivano-Frankivs'k, Ivano-Frankivsk Oblast, Ukraine, 76000
      • Central City Clinical Hospital of Ivano-Frankivsk City Council
  • Zhytomyrs'ka Oblast
    • Zhytomyr, Zhytomyrs'ka Oblast, Ukraine, 10002
      • Hospital №1" of the Zhytomyr City Council

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Age

1. Are ≥18 years of age at the time of randomization

   Disease Characteristics

2. Are currently hospitalized since less or equal than 3 days for COVID-19 respiratory illness

3. Must have a positive SARS-CoV-2 viral infection determination prior to randomisation. For the phase 2 portion of the study only, the test must be performed within 24 hours before randomisation. Test can be a PCR or an antigen test originated from the institution or any government approved testing site. If the original test result is greater than 24 hours from randomisation, a rapid antigen must be performed at bedside by the study team to determine eligibility

   Sex

4. Are men or non-pregnant women Reproductive and Contraceptive agreements and guidance is provided in Appendix 2. Contraceptive use by men or women should be consistent with local regulations for those participating in clinical studies.

   Study Procedures

5. Understand and agree to comply with planned study procedures

6. Agree to the collection of nasopharyngeal swabs and venous blood

   Informed Consent

7. The participant or legally authorized representative give signed informed consent

   Exclusion Criteria:

   Medical Conditions

8. COVID-19 onset of symptoms began more than 10 days before randomisation
9. Currently intubated or intubation is planned within the next 24 hours
10. Have known allergies to any of the components used in the formulation of the interventions
11. Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking intervention
12. Have any co-morbidity requiring surgery within <7 days, or that is considered life- threatening within 29 days

13. Have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study.

    Other Exclusions

14. Have received treatment with a SARS-CoV-2 specific monoclonal antibody
15. Have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed.
16. Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
17. Are pregnant or breast feeding
18. Are investigator site personnel directly affiliated with this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Other: Placebo; matching placebo
Experimental: Active	Biological: IBIO123; 5 or 10 mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 1: Characterize the effect of IBIO123 compared to placebo on safety and tolerability	• Safety assessments such as AEs and SAEs	Baseline to Day 7
Phase 2: Characterize the effect of IBIO123 compared to placebo on SARS-CoV-2 viral load and viral clearance	• Change from baseline to Day 5 (± 2 days) in SARS-CoV-2 viral load	Baseline to Day 5

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 1: Characterize the effect of IBIO123 compared to placebo on SARS-CoV-2 viral load and viral clearance	• Change from baseline to Day 7 (± 2 days) in SARS-CoV-2 viral load	Baseline to Day 7
Phase 2: Characterize the effect of IBIO123 compared to placebo on COVID-19 clinical progression	• Change over time from baseline to Day 29 (± 2 days) in COVID-19 WHO Clinical Progression Scale	Baseline to Day 29
Phase 2: Characterize the effect of IBIO123 compared to placebo on overall participant clinical status	• Proportion (percentage) of participants who experience these events by Day 29; ICU admission; intubation; Mortality; Discharge from Hospitalisation	Baseline to Day 29
Phase 2: Characterize the effect of IBIO123 compared to placebo on safety and tolerability	• Safety assessments such as AEs and SAEs	Baseline to Day 29
Phase 2: Characterize the effect of IBIO123 compared to placebo on length of stay in hospital	• Mean duration of hospitalisation and ICU care (days)	Baseline to Day 29
Phase 2: Characterize the effect of IBIO123 compared to placebo on oxygen supplementation and ventilation needs	Mean duration of oxygen treatment (days) and Incidence of Intubation and Mean duration of Intubation (days)	Baseline to Day 29
Phase 2: Characterize the pharmacokinetics of IBIO123	IBIO123 mean plasma concentration	Days 1, 3, 7 and 29
Phase 2: Characterize the immunogenicity of IBIO123	Assessment of Anti-drug antibodies of IBIO123 at Day 1 and 29	Baseline to Day 29

Collaborators and Investigators

• Sponsor: Immune Biosolutions Inc
• Investigators: Study Director: Sebastien Labbe, PhD, Immune Biosolutions

Study record dates

Study Major Dates

• Study Start (Actual): February 22, 2022
• Primary Completion (Actual): June 27, 2023
• Study Completion (Actual): June 27, 2023

Study Registration Dates

• First Submitted: March 24, 2022
• First Submitted That Met QC Criteria: March 28, 2022
• First Posted (Actual): March 31, 2022

Study Record Updates

• Last Update Posted (Actual): September 13, 2023
• Last Update Submitted That Met QC Criteria: September 10, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: SARS-CoV-2; Hospitalized; IBIO; IBIO123; Inhalation; Severe; Monoclonal antibodies
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: IBIO-INH-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No